Last reviewed · How we verify
Triptorelin Injection
Triptorelin injection is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist.
Triptorelin injection is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist. Used for Prostate cancer, Prepubertal central precocious puberty.
At a glance
| Generic name | Triptorelin Injection |
|---|---|
| Also known as | Androgen Deprivation Therapy, Decapeptyl, Gonapeptyl |
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to GnRH receptors in the pituitary gland, triptorelin injection triggers a cascade of downstream effects that ultimately lead to the suppression of gonadotropin secretion, resulting in decreased levels of sex hormones such as testosterone and estrogen. This mechanism is exploited to treat hormone-sensitive cancers and other conditions.
Approved indications
- Prostate cancer
- Prepubertal central precocious puberty
Common side effects
- Hot flashes
- Injection site reaction
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- COMPASS - COpenhagen MenoPAuSe Study (PHASE2)
- A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorelin Injection CI brief — competitive landscape report
- Triptorelin Injection updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI